Immix Biopharma Posts 95% CR Rate in NEXICART-2, $232M Cash, and Extended Runway
IMMX has more than doubled off its 52-week low of $1.94.
Summary
Immix Biopharma's Q2 2026 report shows a 95% complete response rate in its lead CAR-T trial and a fortified balance sheet with $232M in cash, extending its runway well past the next 12 months.
Key Events · Earnings and Guidance · IMMX
-
NEXICART-2 CR Rate Hits 95%
All four previously MRD-negative patients converted to complete response, bringing the total to 19 out of 20 patients. No relapses observed in patients reaching CR, and all subsequently enrolled patients with available MRD data are MRD-negative at one month.
-
Cash Position Strengthened to $232.1M
Cash, cash equivalents, and short-term investments totaled $232.1 million as of June 30, 2026, following net proceeds of $140.7 million from a May 2026 public offering and $14.0 million from ATM sales.
-
Runway Extended Past 12 Months
Management states existing cash will fund operating expenses and capital requirements for at least the next 12 months from the filing date, supporting the planned Phase 3 trial in newly diagnosed AL amyloidosis.
-
Net Loss Widens on Increased R&D Spend
Net loss for H1 2026 was $21.6 million, up from $11.2 million in H1 2025, driven by higher R&D expenses ($11.3M vs $5.9M) and G&A ($11.9M vs $5.5M) as the company scales clinical and operational activities.
Analysis · IMMX · Life Sciences
Immix Biopharma's Q2 2026 filing reveals a dramatically strengthened position. The NEXICART-2 trial now shows a 95% complete response rate, with all previously MRD-negative patients converting to CR and no relapses observed. Financially, the company holds $232.1 million in cash and short-term investments following a $150 million May 2026 offering, funding operations into at least mid-2027. The net loss widened to $21.6 million for the first half of 2026, driven by increased R&D and G&A spending as the company scales its clinical programs. Executive compensation amendments reflect retention incentives for the CEO and CFO. This filing confirms the company has both the clinical momentum and financial runway to advance toward a Phase 3 trial in newly diagnosed AL amyloidosis.
At the time of this filing, IMMX was trading at $9.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $692M. The 52-week trading range was $1.94 to $12.14. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.